Liquid Biopsy Market was valued at around USD 9.28 billion in 2022 and is expected to rise from USD 10.32 billion in 2023 to reach a value of USD 24.14 billion by 2031, at a CAGR of 11.21% during the forecast period (2024–2031).
Growing Prevalence of Cancer Worldwide to Drive Liquid Biopsy Market
Liquid biopsy market has shown wide potential in the past years in disease application and is anticipated to flourish with more in the years to come. The increasing number of cancers on the global scale and the rising demand for quick and painless diagnostic options is considerably impacting the innovations in the liquid biopsy market.
Liquid biopsies are the latest and improved detection techniques that use any body fluids. The prominent is peripheral blood analysis, while others like cerebrospinal fluid (CSF) for CNS tumors, pleural fluid for metastatic and thoracic cancers, saliva for neck and head tumors, urine for urinary tract cancers, and stool for gastro cancers. It precisely complements the challenges of tissue biopsy and holds the ability to diagnose the disease early, examine efficiency, and observe or monitor the prognosis, which creates promises in clinical implications. Mainly in the oncology area, by detecting and studying tumor-derived biomarkers in the fluids, liquid biopsy characterizes the tumors cellular and genetic phenotypes well and offers real-time, dynamic condition of carcinoma patients.
Download a detailed overview:
https://www.skyquestt.com/sample-request/liquid-biopsy-market
Growing Demand for Improved Privacy and Stronger Security to Drive the Market
Extracellular Vesicles and circulating tumor cells are the two major application areas promising biomarkers in liquid biopsy for diverse cancers. The circulating tumor cells which are cells separating from solid tumor tissues and arriving in the bloodstream or lymphatic system, have been recognized as potential triggers for metastasis of tumors. They can be identified also at an early phase, being related to highlyaggressive biological behavior. Despite their lackin bodily fluids, multiple studies have proven an association with cancer clinical results and CTCs, highlighting the potential to guide decision-making in cancer. Moreover, the CTCs transfer the whole data of the tumor tissue raising its transcriptome, genome, metabolome, and proteome. Hence, CTCs offer abundant potential by offering dynamic and exhaustive information on cancers via the study of easily accessible fluids of the body to enhance diagnostics, monitoring of treatment, and personalized therapy.
Request Free Customization of this report:
https://www.skyquestt.com/speak-with-analyst/liquid-biopsy-market
- In June 2024, a leading precision oncology company, Guardant Health, Incorporation, announced the launch of a fresh version of ‘Guardant360 TissueNext test’. This test is said to expand the quantity of genes identified in a tumor tissue specimen to 498.
- In September 2023, Biocept, an early-stage diagnostics firm in molecular oncology, signed a non-exclusive licensing contract with Plus Therapeutics for its CNSide assay. This expanded the two firms’ present 2022 laboratory services contract.
- In April 2024, QIAGEN N.V. announced a chain of new products to improve cancer research and to allow urine collection & stabilization as a new liquid biopsy technique.
- In November 2023, Illumina Incorporation, a leader in array-based and DNA sequencing technologies, announced a new generation of distributed liquid biopsy assess for genomic profiling. The study assay enabling painless (CGP) comprehensive genomic profiling of (ctDNA) circulating tumor DNA from the blood when tissue testing is unavailable, or to accompany tissue-based test.
View report summary and Table of Contents (TOC):
https://www.skyquestt.com/report/liquid-biopsy-market
The huge potential of liquid biopsy and the introduction of modern technology will allow researchers and scientists to define every section of the tumor circulome with better precision. Currently, liquid biopsies are being embraced as transforming techniques in customized. More improvements will be seen in the liquid biopsy world in the coming years that will integrate AI for more efficiency.
Related Reports:
Augmented, Virtual and Mixed Reality Market
Visit Our Website: https://www.skyquestt.com/
Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/liquid-biopsy-market